JFDA Confirms Safety, Quality Of Ozempic Batches In Local Market
Date
6/26/2024 10:02:38 AM
(MENAFN- Jordan News Agency)
Amman, June 26 (Petra) - The Jordan Food and Drug Administration (JFDA) has confirmed that the batches of the "Semaglutide" preparation, branded as "Ozempic," available in the local
market are approved and have successfully undergone rigorous laboratory procedures and tests, ensuring their quality, safety, and effectiveness.
Nizar Mhaidat, Director-General of the Administration, stated that the counterfeit formulations mentioned in a recent World
health Organization alert were not distributed in the Jordanian market.
He emphasized that the legally approved concentrations of the preparation, 0.25 mg, 0.5 mg, and 1 mg, are registered for the treatment of diabetes. However, its use for treating obesity and weight loss is not approved, and no clinical studies have been provided to support such usage.
Mhaidat highlighted that the JFDA continually emphasizes to relevant health authorities the importance of adhering to the approved indications for prescribing and dispensing the preparation. This ensures patient safety and the continued availability of medication for diabetic patients.
As a precautionary measure, the JFDA, in coordination with the manufacturer, has adopted a guide to educate patients and healthcare providers on distinguishing the original product from counterfeit versions.
For comments, inquiries, or complaints, the JFDA can be contacted via the toll-free complaints line at 117114, email at ..., or WhatsApp at (0795632000).
MENAFN26062024000117011021ID1108376194
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.